Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Plus Chemotherapy and Targeted Therapy in Early Relapse Colorectal Cancer
NCT07604909Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised trial of serplulimab in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 12 months. Started May 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07604909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604909.